The action of a gene called ATDC is required for the development of pancreatic cancer, a new study finds.
The work builds on the theory that many cancers arise when adult cells—to resupply cells lost to injury and inflammation—switch back into more “primitive,” high-growth cell types, like those that drive fetal development.
When this reversion happens in the presence of other genetic mistakes, a repair process meant to start and stop quickly continues unchecked.
New details of this cancer-causing switch to primitive cells, and of the role of ATDC in pancreatic cancer formation, are revealed in a study of mice and human patient samples published online May 2 in the journal Genes & Development.
Led by researchers from NYU School of Medicine and the University of Michigan—Ann Arbor, the study found that ATDC must be active if pancreatic cells, when injured, are to reacquire primitive stem-cell qualities and undergo the early steps that lead to the development of pancreatic cancer.
“We found that deleting the ATDC gene in pancreatic cells resulted in one of the most profound blocks of tumor formation ever observed in a well-known mice model engineered to develop pancreatic ductal adenocarcinoma, or PDA, which faithfully mimics the human disease,” says corresponding author Diane Simeone, MD, director of the Pancreatic Cancer Center of NYU Langone Health’s Perlmutter Cancer Center. “We thought the deletion would slow cancer growth, not completely prevent it.”
The search for better treatment in these cases is especially urgent, says Dr. Simeone, given that PDA has the worst prognosis of any major malignancy and is on track to become the second leading cause of cancer-related death by 2030.
Healing Gone Awry
The study focused on acinar cells in the pancreas that secrete digestive enzymes through a network of partnering ducts into the small intestine. These same digestive enzymes can subject this tissue to low levels of damage. In response, acinar cells have evolved to readily switch back into stem cell types that resemble their high-growth ancestors, a feature that they share with pancreatic duct cells.
This ability to regenerate comes at a price, researchers say, because such cells are prone to become cancerous when they also acquire random DNA changes, including those in the gene KRAS that are known to drive aggressive growth in more than 90 percent of pancreatic cancers.
Specifically, stressed acinar cells are known to temporarily undergo acinar-to-ductal metaplasia, or ADM, a step toward a primitive cell type, to resupply cells. This sets the stage for a second shift into pancreatic intraepithelial neoplasia, or PanIN, in which cells no longer multiply under normal controls.
In the current study, the researchers found that mutant KRAS and other genetic abnormalities induced aggressive pancreatic cancer in 100 percent of study mice when the ATDC gene was present and active, but in none of the same cancer-prone mice lacking the gene. Neither did acinar cells in the ATDC “knock-out” mice undergo ADM or transformation to PanIN.
To get a better look at the early steps in pancreatic cancer formation, the research team artificially caused pancreatitis in mice by treating them with cerulein, a signaling protein fragment that damages pancreatic tissue. ATDC gene expression did not increase right after the damage, but did so a few days later and in line with the timeframe required for acinar cells to reprogram genetically into their ductal cell forebears.
Further experiments confirmed that the expression of ATDC triggers beta-catenin, a cell-signaling protein that, upon receiving the right trigger, activates genes including SOX9. Earlier studies linked SOX9 to the development of ductal stem cells and to the aggressive growth seen in PDA. Consistent with this work, the current study found that the inability of cells lacking ATDCto become cancerous was due to their inability to induce SOX9 expression.
The authors also examined ATDC expression in ADM lesions from 12 samples of human pancreatic tissue. The team found it to be more active in human ADM lesions along with beta-catenin and SOX9, and its activation increased further during the transition of ADM into human pancreatic ductal adenocarcinoma.
The findings, says Dr. Simeone, identify ATDC, beta-catenin, SOX9, and their signaling partners as potential targets in the design of new treatment approaches and prevention strategies for pancreatic cancer.
The Latest on: Pancreatic cancer
via Google News
The Latest on: Pancreatic cancer
- $1.5 million raised for cancer research at 7th annual Tour de Pier in Manhattan Beach on May 20, 2019 at 3:35 pm
The event raised $1.5 million on Saturday for three nonprofts: the Hirshberg Foundation for Pancreatic Cancer Research; Cancer Support Community Redondo Beach and the Uncle Kory Brain Cancer ... […]
- Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features on May 20, 2019 at 3:12 pm
Pancreatic cancer is a lethal disease, with fewer than 7% of patients surviving beyond 5 years following diagnosis. Immune responses are known to influence tumour progression. The dynamic interaction ... […]
- Familiar, Safe Drug Seen Improving Pancreatic Cancer Outcomes on May 20, 2019 at 10:08 am
SAN DIEGO -- Non-selective beta-adrenergic blockade was linked to improved outcomes for patients with a common form of pancreatic cancer, according to a retrospective analysis presented here. In a ... […]
- The List: Mayo Clinic doc talks pancreatic cancer on May 20, 2019 at 5:59 am
Florida will see an estimated 130,000 new cancer cases in the state this year, according to the American Cancer Society — and many of them will be in Duval County, which has the highest cancer rate in ... […]
- Loss of Disabled-2 Expression in Pancreatic Cancer Progression on May 17, 2019 at 2:10 am
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer type characterized by rapid metastasis and resistance to chemotherapy, properties that are shared by cancer stem cells (CSCs). In ... […]
- Early removal of some pancreatic cysts could decrease cancer risk, save lives on May 15, 2019 at 5:08 am
CT scan of a pancreas that shows enlarged pancreatic duct. Credit: Johns Hopkins Medicine The findings, they say, are not yet proof of the concept, but do strongly suggest that removing so-called ... […]
- ERYTECH Announces FDA’s Authorization to Proceed with Phase 3 Trial for Eryaspase in Pancreatic Cancer in the United States on May 13, 2019 at 1:00 pm
Investigational New Drug Application reviewed and accepted Enrollment of US patients expected to begin in Q3 2019 Clinical trial authorizations now obtained in all twelve participating countries LYON, ... […]
- Money raised in Norwalk for pancreatic cancer research on May 12, 2019 at 10:00 am
NORWALK, Conn. (WTNH) - Runners and walkers were raising money for pancreatic cancer research on Sunday. The Norwalk Steps For a Cure got underway at 8:30 a.m. at Calf Pasture Beach Park. Related ... […]
- Pancreatic cancer survival rates in Nova Scotia continue to fall, remain lowest in Canada on May 12, 2019 at 5:27 am
Healthcare professionals from across the Maritimes and beyond gathered for the Eastern Canada Pancreatic Cancer Symposium. The symposium aims to examine the state of healthcare, looking at the current ... […]
- Researchers hope new vaccine could improve odds for pancreatic cancer on May 10, 2019 at 4:40 pm
Bruce Toma, 69, is making plans for traveling and sprucing up his house. That's a far cry from the fall of 2017, when he was diagnosed with pancreatic cancer. The disease and chemo left him in ... […]
via Bing News